### 中新网金华7月7日电
在科技创新与产业升级的双重驱动下，生物医药产业正经历着一场深刻的变革。近日，在浙江省金华市召开的生物医药产业研讨会上，民建会员们围绕“新质生产力驱动下的生物医药产业变革和机遇”这一主题，展开了深入的讨论与交流。
新质生产力，即通过技术创新、模式创新和管理创新，实现产业结构优化升级、生产效率提升和产品质量升级的能力。在生物医药领域，这意味着需要依托前沿的生物技术、信息技术和大数据分析，推动新药研发、精准医疗、生物制造等领域的创新，以满足日益增长的健康需求和提高医疗服务质量。
民建会员们指出，生物医药产业的变革和机遇主要体现在以下几个方面：
1. **精准医疗的普及**：通过基因测序、生物信息分析等手段，实现个性化医疗，精准治疗，提高治疗效果和患者生活质量。
2. **创新药物的研发**：利用人工智能、合成生物学等技术，加速新药的研发过程，降低研发成本，提高新药上市速度。
3. **生物技术的融合**：生物技术与信息技术、材料科学的深度融合，推动生物制造、生物信息、生物材料等新兴领域的快速发展。
4. **产业生态的构建**：通过产学研用深度融合，构建开放、协同、共享的生物医药产业生态，促进技术创新成果的快速转化和应用。
面对这一系列的变革和机遇，民建会员们强调了政策支持、资金投入、人才培养和国际合作的重要性。他们呼吁政府、企业和社会各界共同努力，为生物医药产业的发展创造良好的环境，推动技术创新和产业升级，以实现健康中国战略的目标。
本次研讨会不仅为业界专家和企业家提供了交流与合作的平台，也进一步激发了社会各界对生物医药产业未来发展的关注与期待。未来，随着科技的不断进步和政策的持续支持，生物医药产业有望在新质生产力的驱动下，迎来更加广阔的发展前景。
英语如下：
### “Driving Forces of New Quality Productivity: Transformation and Opportunities in the Biopharmaceutical Industry”
### JI’AN, ZHEJIANG, JULY 7, 2023
Under the dual impetus of innovation in science and technology and industrial upgrading, the biopharmaceutical industry is undergoing a profound transformation. At a recent biopharmaceutical industry forum held in JI’AN, ZHEJIANG province, members of the China Democratic People’s Party (CPDP) engaged in in-depth discussions and exchanges around the theme of “Transformation and Opportunities in the Biopharmaceutical Industry Driven by New Quality Productivity.”
New quality productivity refers to the capability of optimizing industrial structure, enhancing production efficiency, and upgrading product quality through technological innovation, model innovation, and management innovation. In the biopharmaceutical sector, this means leveraging cutting-edge biotechnology, information technology, and big data analysis to drive innovation in new drug development, precision medicine, and biomanufacturing, thereby meeting growing health demands and improving medical service quality.
Members of the CPDP highlighted several key aspects of the industry’s transformation and opportunities:
1. **Widespread Adoption of Precision Medicine**: Utilizing genomic sequencing, bioinformatics analysis, and other techniques to provide personalized medical treatment, enhancing treatment efficacy and improving patients’ quality of life.
2. **Accelerated Development of Innovative Drugs**: Leveraging artificial intelligence, synthetic biology, and other technologies to expedite the drug development process, reducing costs, and speeding up the time to market for new drugs.
3. **Integration of Biotechnology**: The fusion of biotechnology with information technology, materials science, driving the rapid development of emerging fields such as biomanufacturing, bioinformatics, and biomaterials.
4. **Building an Industry Ecosystem**: Promoting the integration of research, industry, academia, and application through a collaborative, open, and sharing ecosystem to facilitate the rapid translation and application of technological innovations.
Facing this series of transformations and opportunities, members of the CPDP emphasized the importance of policy support, capital investment, talent development, and international cooperation. They called for joint efforts from governments, businesses, and society to create a conducive environment for the development of the biopharmaceutical industry, driving technological innovation and industrial upgrading to achieve the goals of the Healthy China strategy.
This forum not only provided a platform for industry experts and entrepreneurs to exchange and collaborate but also further sparked public interest and anticipation for the future development of the biopharmaceutical industry. Looking ahead, with ongoing technological advancements and policy support, the biopharmaceutical industry is poised to experience a more expansive future under the drive of new quality productivity.
【来源】http://www.chinanews.com/gn/2024/07-07/10247341.shtml
Views: 4